Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 3/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | FGB | P02675 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16268565 | 0.89 | MAPT (0.37) | KMT2AMEN1MAPTMAPK1HTT | |
| SCHEMBL16268717 | 0.82 | ALDH1A1 (0.42) | SNCAKLK7MAOAMAOBKMT2A | |
| SCHEMBL16268343 | 0.81 | SNCA (0.48) | SNCAMAOAMAOBKMT2AMEN1 | |
| SCHEMBL16269385 | 0.79 | SNCA (0.43) | SNCAKLK7MAOAMAOBKMT2A | |
| SCHEMBL17687311 | 0.74 | SNCA (0.39) | SNCAKLK7MAOAMAOBKMT2A | |
| SCHEMBL16268272 | 0.73 | SNCA (0.51) | SNCAMAOAMAOBKMT2AMEN1 | |
| SCHEMBL16268703 | 0.69 | CES1 (0.37) | SNCAMAOAMAOBKMT2AMEN1 | |
| SCHEMBL16268763 | 0.69 | SNCA (0.49) | SNCAMAOAMAOBKMT2AMEN1 | |
| SCHEMBL16268569 | 0.68 | SNCA (0.48) | SNCAMAOAMAOBKMT2AMEN1 | |
| SCHEMBL16268341 | 0.68 | MAPT (0.38) | SNCAKMT2AMEN1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004118-B1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2018-12-19 | — | — | EP | claimed |
| US-9827249-B2 | Use of condensed benzo[B]thiazine derivatives as cytoprotectants | ARANDA PHARMA LTD (FI) | 2017-11-28 | — | — | US | claimed |
| US-20160106754-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2016-04-21 | — | — | US | claimed |
| EP-3004118-B1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2018-12-19 | — | — | EP | disclosed |
| US-9827249-B2 | Use of condensed benzo[B]thiazine derivatives as cytoprotectants | ARANDA PHARMA LTD (FI) | 2017-11-28 | — | — | US | disclosed |
| US-9827249-B2 | Use of condensed benzo[B]thiazine derivatives as cytoprotectants | ARANDA PHARMA LTD (FI) | 2017-11-28 | — | — | US | disclosed |
| US-20160106754-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2016-04-21 | — | — | US | disclosed |
| US-20160106754-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2016-04-21 | — | — | US | disclosed |
| EP-3004118-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | Aranda Pharma Ltd (FI) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014191632-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | MEDEIA THERAPEUTICS LTD (FI) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106754-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | TXN2, GPX4, NQO1 | SNCA 337/4885KLK7 3387/4885MAOA 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.